Identification of 3',4',5'-trihydroxyflavone as an mammalian target of rapamycin inhibitor and its suppressive effects on dextran sulfate sodium-induced ulcerative colitis.
Animals
Anti-Inflammatory Agents
/ pharmacology
Autophagy
/ drug effects
Cell Survival
/ drug effects
Colitis, Ulcerative
/ chemically induced
Colon
/ drug effects
Dextran Sulfate
Flavones
/ pharmacology
HCT116 Cells
HT29 Cells
Humans
Interleukin-1beta
/ genetics
Lipopolysaccharides
/ pharmacology
Macrophage Activation
/ drug effects
Male
Mice
Mice, Inbred C57BL
Nitric Oxide
/ immunology
Nitric Oxide Synthase Type II
/ genetics
RAW 264.7 Cells
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Tumor Necrosis Factor-alpha
/ genetics
3′,4′,5′-Trihydroxyflavone
Autophagy
DSS-induced mouse colitis model
Inflammatory bowel disease
Mammalian target of rapamycin
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
16
02
2020
revised:
29
03
2020
accepted:
15
04
2020
pubmed:
26
4
2020
medline:
11
3
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Flavone derivatives have been shown to possess anti-inflammatory properties in various inflammation model systems; however, their underlying molecular mechanisms remain elusive. In this study, a flavone derivative 3',4',5'-trihydroxyflavone (THF; NJK16003) was synthesized, and its anti-inflammatory effects and molecular targets were investigated using in vitro systems and an in vivo colitis model. NJK16003 showed potent anti-inflammatory activities in cell-based assays using macrophages. In vitro enzyme activity assays using various inflammation-related kinases revealed the mammalian target of rapamycin (mTOR) as a possible molecular target. Treatment of RAW264.7 cells with NJK16003 resulted in an increase in light chain 3B protein lipidation and a decrease in p62 protein levels and ribosomal S6 kinase phosphorylation, indicating that NJK16003 induces autophagy through mTOR inhibition. NJK16003 treatment resulted in significant induction of autophagy and suppression of inflammatory responses in intestinal epithelial cells. Autophagy induction has been shown to alleviate colitis by suppressing inflammatory responses and apoptotic cell death of intestinal epithelial cells. Indeed, inflammatory responses and intestinal epithelial cell death in our DSS-induced colitis mouse model were significantly suppressed by NJK16003 treatment. Our results indicate that NJK16003 could suppress inflammation by inducing autophagy through its mTOR inhibitory activity. These results suggest that NJK16003 could be a possible therapeutic agent for the treatment of inflammatory bowel diseases including colitis.
Identifiants
pubmed: 32334388
pii: S1567-5769(20)30436-7
doi: 10.1016/j.intimp.2020.106524
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Flavones
0
IL1B protein, mouse
0
Interleukin-1beta
0
Lipopolysaccharides
0
Tnf protein, mouse
0
Tumor Necrosis Factor-alpha
0
Nitric Oxide
31C4KY9ESH
Dextran Sulfate
9042-14-2
Nitric Oxide Synthase Type II
EC 1.14.13.39
Nos2 protein, mouse
EC 1.14.13.39
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106524Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.